Production (Stage)
Brainstorm Cell Therapeutics Inc.
BCLI
$1.22
-$0.025-2.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.63% | 32.39% | 14.45% | 42.75% | 35.21% |
| Total Depreciation and Amortization | -12.98% | -9.43% | -5.95% | -5.47% | -5.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.99% | -93.67% | 341.17% | 62.24% | 209.57% |
| Change in Net Operating Assets | 130.67% | 129.47% | -61.21% | -13,275.00% | -373.16% |
| Cash from Operations | 60.78% | 55.55% | 48.08% | 28.73% | 0.42% |
| Capital Expenditure | -- | -- | -- | -1,700.00% | 10.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -92.95% | -93.35% | -93.22% |
| Cash from Investing | -93.62% | -99.45% | -93.54% | -93.94% | -93.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -66.57% | -58.02% | -35.32% | 97.99% | 427.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -53.44% | -58.02% | -35.32% | 97.99% | 427.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.60% | -256.24% | 70.12% | 136.67% | 91.93% |